65 Similarly, a 48-week trial of lovastatin in 77 PD patients, showed a trend in reduction of UPDRS part III scores which did not reach statistical significance. 66 Inflammatory biomarkers were not assessed as a part of either of these trials.
← all excerpts
Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents.
1
—
—